Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Session Chair

Ticiana Leal, MD

Associate Professor of Medicine
Director, Thoracic Medical Oncology Program
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Leal and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Leal's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Ticiana Leal, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai, Inc.; EMD Serono, Inc.; Genentech; Janssen; Jazz Pharmaceuticals, Inc.; Lilly; Merck; Mirati Therapeutics, Inc.; Novocure; Roche; Takeda

Faculty

Jennifer W. Carlisle, MD

Assistant Professor of Medicine
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Carlisle and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Carlisle's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Jennifer W. Carlisle, MD, has no relevant financial relationships.

Aditya Juloori, MD

Assistant Professor
Department of Radiation and Cellular Oncology
University of Chicago
Chicago, Illinois

Disclosures

Aditya Juloori, MD, has the following relevant financial relationships:
Consultant or advisor for: Aqualung Therapeutics; GE Healthcare; Isoray
Research funding from: AstraZeneca

Misty Dawn Shields, MD, PhD

Assistant Professor of Clinical Medicine
Division of Hematology/Oncology
Associate Member, Experimental and Developmental Therapeutics
Indiana University School of Medicine
Indiana University Health Physicians
Indianapolis, Indiana

Disclosures

Misty Dawn Shields, MD, PhD, has no relevant financial relationships.

Editor

John Churchwell, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, PhD, has the following relevant financial relationships:
Formerly employed by an ineligible company: Medtronic, Inc.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC / CE

Management of Small Cell Lung Cancer

Authors: Ticiana Leal, MD; Jennifer W. Carlisle, MD; Aditya Juloori, MD; Misty Dawn Shields, MD, PhD
CME / ABIM MOC / CE Released: 3/31/2023
Valid for credit through: 3/31/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.50 ABIM MOC points

Nurses - 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, radiologists (including radiation oncologists), nurses/nurse practitioners (NPs), physician assistants (PAs), and pharmacists.

The goal of this activity is for the learner to be better able to understand the roles of the interprofessional team in tailoring the management of patients with small cell lung cancer (SCLC).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data evaluating regimens used to treat patients with SCLC
- Emergence of novel therapies for SCLC
Have greater competence related to
- Tailoring therapy for patients with SCLC
Demonstrate greater confidence in their ability to
- Leverage the use of an interprofessional team to optimize outcomes in patients with SCLC

Disclosures

Disclosures for additional planners can be found here.

Session Chair

Ticiana Leal, MD

Associate Professor of Medicine
Director, Thoracic Medical Oncology Program
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Leal and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Leal's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Ticiana Leal, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai, Inc.; EMD Serono, Inc.; Genentech; Janssen; Jazz Pharmaceuticals, Inc.; Lilly; Merck; Mirati Therapeutics, Inc.; Novocure; Roche; Takeda

Faculty

Jennifer W. Carlisle, MD

Assistant Professor of Medicine
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Carlisle and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Carlisle's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Jennifer W. Carlisle, MD, has no relevant financial relationships.

Aditya Juloori, MD

Assistant Professor
Department of Radiation and Cellular Oncology
University of Chicago
Chicago, Illinois

Disclosures

Aditya Juloori, MD, has the following relevant financial relationships:
Consultant or advisor for: Aqualung Therapeutics; GE Healthcare; Isoray
Research funding from: AstraZeneca

Misty Dawn Shields, MD, PhD

Assistant Professor of Clinical Medicine
Division of Hematology/Oncology
Associate Member, Experimental and Developmental Therapeutics
Indiana University School of Medicine
Indiana University Health Physicians
Indianapolis, Indiana

Disclosures

Misty Dawn Shields, MD, PhD, has no relevant financial relationships.

Editor

John Churchwell, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, PhD, has the following relevant financial relationships:
Formerly employed by an ineligible company: Medtronic, Inc.

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-23-084-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Management of Small Cell Lung Cancer

Authors: Ticiana Leal, MD; Jennifer W. Carlisle, MD; Aditya Juloori, MD; Misty Dawn Shields, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/31/2023

Valid for credit through: 3/31/2024, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Standard Management of Small Cell Lung Cancer

Find out the latest about standard management of SCLC in this informative presentation.
Jennifer W. Carlisle, MD

The Evolving Role of Radiation in the Treatment of Small Cell Lung Cancer

Get ready to take your clinical skills to the next level with this discussion focused on the evolving landscape of radiation treatment in SCLC.
Aditya Juloori, MD

Novel Approaches to Small Cell Lung Cancer

Keep pace with rapidly changing strategies for treatment of SCLC with this succinct presentation.
Misty Dawn Shields, MD, PhD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 6

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Session Chair

Ticiana Leal, MD

Faculty

Jennifer W. Carlisle, MD

Aditya Juloori, MD

Misty Dawn Shields, MD, PhD

Editor

John Churchwell, PhD

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Management of Small Cell Lung Cancer

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Session Chair

Ticiana Leal, MD

Faculty

Jennifer W. Carlisle, MD

Aditya Juloori, MD

Misty Dawn Shields, MD, PhD

Editor

John Churchwell, PhD

Compliance Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Management of Small Cell Lung Cancer

Contents of This CME Activity

Standard Management of Small Cell Lung Cancer

The Evolving Role of Radiation in the Treatment of Small Cell Lung Cancer

Novel Approaches to Small Cell Lung Cancer

Learning Feedback Questions